Company

MediMabBio Inc.

MediMabBio develops immunotherapies for cancer.

About

MediMabBio develops immuno-oncology drugs targeting advanced and solid tumors. The company was founded in 2017 and is based in Seongnam, South Korea. It raised KRW 25.6 billion in series B funding in October 2025.

4Funding rounds

15Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in